ADVERSE EVENTS IN PATIENTS WITH METASTATIC PANCREATIC CANCER RECEIVING LIPOSOMAL IRINOTECAN: UNDERSTANDING THE OCCURRENCE AND HOW MANAGEMENT AFFECTS PATIENT OUTCOMES

被引：0
|
作者：
Jameson, Gayle [1 ]
Caldwell, Lana [1 ]
Mirakhur, Beloo [2 ]
de Jong, Floris [3 ]
Ansaldo, Karen [1 ]
机构：
[1] HonorHealth, Scottsdale, AZ USA
[2] Ipsen Biopharmaceut, Basking Ridge, NJ USA
[3] Shire GmbH, Zug, Switzerland
来源：
ONCOLOGY NURSING FORUM | 2018年 / 45卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IS-15
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A multicenter chart review study of patients with metastatic pancreatic ductal adenocarcinoma receiving liposomal irinotecan after gemcitabine-based therapy.
    Yu, Kenneth H.
    Hendifar, Andrew Eugene
    Alese, Olatunji B.
    Draper, Amber
    Abdelrahim, Maen
    Burns, Ethan
    Khan, Gazala Naaz
    Cockrum, Paul
    Bhak, Rachel
    DerSarkissian, Maral
    Nguyen, Catherine
    Duh, Mei Sheng
    Bahary, Nathan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Cardiovascular risk factors and occurrence of cardiovascular adverse events in patients with advanced breast cancer receiving chemotherapy
    Breekveldt-Postma, Nancy N.
    Sukel, Myrthe P. P.
    Erkens, Joelle A.
    van der Linden, Paul D.
    Beiderbeck, Annette B.
    MC Herings, Ron
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S258 - S258
  • [23] Integrated population pharmacokinetic modelling of liposomal irinotecan in patients with various tumour types, including untreated metastatic pancreatic cancer (mPC)
    Macarulla, T.
    Brendel, K.
    Lieu, C.
    Wainberg, Z.
    Dayyani, F.
    Zhang, B.
    Belanger, B.
    Moore, Y.
    Pedret-Dunn, A.
    Maxwell, F.
    Dean, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] IMPACT OF TREATMENT SEQUENCE ON OVERALL SURVIVAL IN METASTATIC PANCREATIC CANCER PATIENTS TREATED WITH LIPOSOMAL IRINOTECAN IN THE REAL-WORLD SETTING
    Kim, G. P.
    Surinach, A.
    Corvino, F. A.
    Cockrum, P.
    VALUE IN HEALTH, 2019, 22 : S58 - S58
  • [25] Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta-analysis of real-world evidence
    Gupta, Amol
    De Jesus-Acosta, Ana
    Le, Dung
    Pishvaian, Michael
    Zaidi, Neeha
    Zheng, Lei
    Laheru, Daniel
    CANCER, 2024, 130 (21) : 3734 - 3744
  • [26] The Importance of Keeping Patients With Metastatic Colorectal Cancer on Treatment Through the Management of Adverse Events
    Grothey, Axel
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (10) : 15 - 19
  • [27] Management of Adverse Events in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib and Clinical Outcomes
    Arakawa-Todo, Maki
    Yoshizawa, Takahiko
    Zennami, Kenji
    Nishikawa, Genya
    Kato, Yoshiharu
    Kobayashi, Ikuo
    Kajikawa, Keishi
    Yamada, Yoshiaki
    Matsuura, Katsuhiko
    Tsukiyama, Ikuto
    Saito, Hiroko
    Hasegawa, Takaaki
    Nakamura, Kogenta
    Sumitomo, Makoto
    ANTICANCER RESEARCH, 2013, 33 (11) : 5043 - 5050
  • [28] Understanding extended duration of therapy (DOT) among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens
    Mokrzecky, Cheryl
    Cockrum, Paul
    Surinach, Andy
    Becerra, Carlos Roberto
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [29] ROBUSTNESS OF OUTCOMES IN INDIRECT COMPARISON METHODS OF PEGYLATED LIPOSOMAL IRINOTECAN FOR THE TREATMENT OF METASTATIC PANCREATIC CANCER IN PATIENTS WHO HAVE PROGRESSED FOLLOWING GEMCITABINE-BASED THERAPY
    Felix, Parreia J.
    Andreozzi, V
    Henriques, J.
    Amorim, A. P.
    Massetti, M.
    VALUE IN HEALTH, 2024, 27 (12) : S360 - S360
  • [30] Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab
    Huezin H. Lim
    Ashley M. Hopkins
    Andrew Rowland
    Hoi Y. Yuen
    Christos S. Karapetis
    Michael J. Sorich
    Targeted Oncology, 2019, 14 : 743 - 748
12345